AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1 (currently amended). A pharmaceutical formulation comprising an effective amount of acetylsalicylic acid and a compound of formula I,

$R^1O(O)C\text{-}CH_2\text{-}(R)Cgl\text{-}Aze\text{-}Pab\text{-}R^2$ I

wherein

R^1 represents $-R^3$ or $-A^1C(O)N(R^4)R^5$ or $-A^1C(O)OR^4$;

A^1 represents C_{1-5} alkylene;

R^2 (which replaces one of the hydrogen atoms in the amidino unit of Pab-H) represents OH, $OC(O)R^6$, $C(O)OR^7$ or $C(O)OCH(R^8)OC(O)R^9$;

R^3 represents H, C_{1-10} alkyl, or C_{1-3} alkylphenyl (which latter group is optionally substituted by C_{1-6} alkyl, C_{1-6} alkoxy, nitro or halogen);

R^4 and R^5 independently represent H, C_{1-6} ailcyl, phenyl, 2-naphthyl or, when R^1 represents $-A^1C(O)N(R^4)R^5$, together with the nitrogen atom to which they are attached represent pyrrolidinyl or piperidinyl;

R^6 represents C_{1-17} alkyl, phenyl or 2-naphthyl (all of which are optionally substituted by C_{1-6} alkyl or halogen);

R^7 represents 2-naphthyl, phenyl, C_{1-3} alkyiphenyl (which latter three groups are optionally substituted by C_{1-6} alkyl, C_{1-6} alkoxy, nitro or halogen), or C_{1-12} alkyl (which latter group is optionally substituted by C_{1-6} alkoxy, C_{1-6} acyloxy or halogen);

R^8 represents H or C_{1-4} alkyl; and

R^9 represents 2-naphthyl, phenyl, C_{1-6} alkoxy or C_{1-8} alkyl (which latter group is

optionally substituted by halogen, C_{1-6} alkoxy or C_{1-6} acyloxy); provided that when R^1 represents R^3, R^3 represents benzyl, methyl, ethyl, *n-butyl* or *n-hexyl* and R^2 represents $C(O)OR^7$, then R^7 does not represent benzyl;

or a pharmaceutically-acceptable salt thereof.

2 (currently amended). A formulation~~compound of formula I~~, as defined in Claim 1, wherein, in the compound of formula I, A^1 represents C_{1-3} alkylene when R^1 represents $-A^1C(O)N(R^4)R^5$.

3 (currently amended). A formulation~~compound of formula I~~, as defined in Claim 1, wherein, in the compound of formula I, R^4 represents H or C_{1-6} alkyl when R^1 represents $-A^1C(O)N(R^4)R^5$.

4 (currently amended). A formulation~~compound of formula I~~, as defined in Claim 1, wherein, in the compound of formula I, R^5 represents C_{1-6} alkyl or C_{4-6} cycloalkyl when R^1 represents $-A^1C(O)N(R^4)R^5$.

5 (currently amended). A formulation~~compound of formula I~~, as defined in Claim 1, wherein, in the compound of formula I, R^4 and R^5 together represent pyrrolidinyl when R^1 represents $-A^1C(O)N(R^4)R^5$.

6 (currently amended). A formulation~~compound of formula I~~, as defined in Claim 2, wherein, in the compound of formula I, A^1 represents C_{1-3} alkylene, and R^4

represents H or C_{1-3} alkyl and R^5 represents C_{2-6} alkyl or C_{5-6} cycloalkyl, or R^4 and R^5 together represent pyrrolidinyl.

7 (currently amended). A formulation~~compound of formula I~~, as defined in Claim 1, wherein, in the compound of formula I, A^1 represents C_{1-5} alkylene when R^1 represents $-A^1C(O)OR^4$.

8 (currently amended). A formulation~~compound of formula I~~, as defined in Claim 1, wherein, in the compound of formula I, R^4 represents C_{1-6} alkyl when R^1 represents $-A^1C(O)OR^4$.

9 (currently amended). A formulation~~compound of formula I~~, as defined in Claim 7, wherein A^1 represents C_{1-5} alkylene and R^4 represents C_{1-4} alkyl.

10 (currently amended). A formulation~~compound of formula I~~, as defined in Claim 1, wherein, in the compound of formula I, R^3 represents H, C_{1-10} alkyl (which latter group may be linear or, when there are a sufficient number of carbon atoms, may be branched and/or be partially cyclic or cyclic), or C_{1-3} alkylphenyl (which latter groups is optionally substituted, may be linear or, when there are a sufficient number of carbon atoms, be branched), when R^1 represents R^3.

11 (currently amended). A formulation~~compound~~ as claimed in Claim 1, wherein, in the compound of formula I, R^1 represents H, linear C_{1-10} alkyl, branched C_{3-10}

alkyl, partially cyclic C_{4-10} alkyl, C_{4-10} cycloalkyl, optionally substituted linear C_{1-3} alkylphenyl, optionally substituted branched C_3 alkylphenyl.

12 (currently amended). A formulation~~compound~~ as claimed in Claim 11, wherein R^1 represents linear C_{1-6} alkyl, C_{6-10} cycloalkyl, or optionally substituted linear C_{1-3} alkylphenyl.

13 (currently amended). A formulation~~compound of formula I~~, as defined in Claim 1, wherein, in the compound of formula I, R^2 represents OH.

14 (currently amended). A formulation~~compound of formula I~~, as defined in Claim 1, wherein, in the compound of formula I, R^6 represents optionally substituted phenyl or C_{1-17} alkyl (which latter group may be linear or, when there are a sufficient number of carbon atoms, may be branched, be cyclic or partially cyclic, and/or be saturated or unsaturated) when R^2 represents $OC(O)R^6$.

15 (currently amended). A formulation~~compound~~ as claimed in Claim 14 wherein R^6 represents optionally substituted phenyl, linear C_{1-4} alkyl, branched C_{1-3} alkyl or *cis*-oleyl.

16 (currently amended). A formulation~~compound~~ as claimed in Claim 15 wherein R^6 represents linear C_{1-3} alkyl or branched C_3 alkyl.

17 (currently amended). A formulation~~compound of formula I~~, as defined in Claim 1, wherein, in the compound of formula I, R^7 represents optionally substituted phenyl, C_{1-12} alkyl (which latter group is optionally substituted, may be linear or, when there are a sufficient number of carbon atoms, may be branched, cyclic or partially cyclic, and/or saturated or unsaturated), or C_{1-3} alkylphenyl (which latter group is optionally substituted, may be linear or, when there are a sufficient number of carbon atoms, may be branched) when R^2 represents $C(O)OR^7$.

18 (currently amended). A formulation~~compound as claimed~~ in Claim 17 wherein R^7 represents optionally substituted and/or optionally unsaturated linear C_{1-4} alkyl or optionally substituted and/or optionally unsaturated branched C_{3-4} alkyl, optionally substituted phenyl, or optionally substituted linear C_{1-3} alkylphenyl or optionally substituted branched C_3 alkylphenyl.

19 (currently amended). A formulation~~compound~~ as claimed in Claim 18 wherein R^7 represents optionally substituted linear C_{1-4} alkyl or optionally substituted branched C_{3-4} alkyl, optionally substituted linear C_{1-3} alkylphenyl or branched C_3 alkylphenyl.

20 (currently amended). A formulation~~compound of formula I~~, as defined in Claim 1, wherein, in the compound of formula I, R^8 represents H or methyl, when R^2 represents $C(O)OCH(R^8)OC(O)R^9$.

21 (currently amended). A formulation~~compound of formula I~~, as defined in Claim 1, wherein, in the compound of formula I, R^9 represents phenyl, or C_{1-8} alkyl (which latter group is optionally substituted, may be linear or, when there are a sufficient number of carbon atoms, may be branched and/or cyclic or partially cyclic) when R^2 represents $C(O)OCH(R^8)OC(O)R^9$.

22 (currently amended). A formulation~~compound of formula I~~, as defined in Claim 20 wherein R^8 represents H or methyl and R^9 represents phenyl, C_{5-7} cycloalkyl, linear C_{1-6} alkyl, branched C_{3-6} alkyl or partially cyclic C_{7-8} alkyl.

23 (currently amended). A formulation~~compound~~ as claimed in Claim 22 wherein R^8 represents H and R^9 represents C_{5-7} cycloalkyl, linear C_{1-6} alkyl or partially cyclic C_{7-8} alkyl.

24 (currently amended). A formulation~~compound~~ as claimed in Claim 1 wherein, in the compound of formula I, when R^1 represents R^3 and R^3 represents optionally substituted C_{1-3} alkylphenyl, the optional substituent C_{1-6} alkyl.

25 (currently amended). A formulation~~compound~~ as claimed in Claim 24 wherein the substituent is methyl.

26 (currently amended). A formulation~~compound~~ as claimed in Claim 1 wherein, in the compound of formula I, when R^2 represents $C(O)OR^7$ and R^7 represents

optionally subsituted C_{1-12} alkyl, the optional substituent is selected from halogen and C_{1-6} alkoxy.

27 (currently amended). A formulation~~compound~~ as claimed in Claim 26 wherein the substituent is selected from chloro and methoxy.

28 (currently amended). A formulation~~compound~~ as claimed in Claim 1 wherein, in the compound of formula I, when R^2 represents $C(O)OR^7$ and R^7 represents optionally subsituted phenyl, the optional substituent is selected from C_{1-6} alkyl, C_{1-6} alkoxy and halogen.

29 (currently amended). A formulation~~compound~~ as claimed in Claim 28 wherein the substituent is selected from methyl, methoxy and chloro.

30 (currently amended). A formulation~~compound~~ as claimed in Claim 1 wherein, in the compound of formula I, when R^2 represents $C(O)OR^7$ and R^7 represents optionally subsituted C_{1-3} alkylphenyl, the optional substituent is nitro.

31 (currently amended). A formulation~~compound~~ as claimed in Claim 1 wherein the compound of formula I~~which~~ is

$EtOOCCH_2$-(*R*)Cgl-Aze-Pab-$COOCH_2CH = CH_2$;

n$PrOOCCH_2$-(*R*)Cgl-Aze-Pab-$COOCH_2CH = CH_2$;

t$BuOOCCH_2$-(*R*)Cgl-Aze-Pab-$COOCH_2CH=CH_2$;

EtOOCCH$_2$-(*R*)Cgl-Aze-Pab-COOEt

EtOOCCH$_2$-(*R*)Cgl-Aze-Pab-COO-*n*Bu;

PrlC(O)CH$_2$CH$_2$CH$_2$OOCCH$_2$-(*R*)Cgl-Aze-Pab-Z;

ChNHC(O)CH$_2$OOCCH$_2$-(*R*)Cgl-Aze-Pab-Z;

(*n*Pr)$_2$NC(O)CH2OOCCH$_2$-(*R*)Cgl-Aze-Pab-COOCH$_2$OOCC(CH$_3$)$_3$;

EtOOCCH$_2$-(*R*)Cgl-Aze-Pab-COOCH$_2$OOCC(CH$_3$)$_3$;

EtOOCCH$_2$-(*R*)Cgl-Aze-Pab-COOCH(CH$_3$)OOCCH$_3$;

MeOOCCH$_2$-(*R*)Cgl-Aze-Pab-OOCPh;

MeOOCCH$_2$-(*R*)Cgl-Aze-Pab-OH;

EtOOCCH$_2$-(*R*)Cgl-Aze-Pab-OH;

BnOOCCH$_2$-(*R*)Cgl-Aze-Pab-OH;

*n*PrOOCCH$_2$-(*R*)Cgl-Aze-Pab-Z;

*n*PrOOCCH$_2$-(*R*)Cgl-Aze-Pab-OH;

*i*PROOCCH$_2$-(*R*)Cgl-Aze-Pab-OH;

*t*BuOOCCH$_2$-(*R*)Cgl-Aze-Pab-OH;

(*n*Pr)$_2$NCOCH$_2$OOCCH$_2$-(*R*)Cgl-Aze-Pab-OH;

ChNHCOCH$_2$OOCCH$_2$-(*R*)Cgl-Aze-Pab-OH;

EtOOCCH$_2$-(*R*)Cgl-Aze-Pab-OAc;

HOOCCH$_2$-(*R*)Cgl-Aze-Pab-OH;

HOOCCH$_2$-(*R*)Cgl-Aze-Pab-O-*cis*-Oleyl;

Cyclooctyl-OOCCH$_2$-(*R*)Cgl-Aze-Pab-Z;

*t*BuCH2OOCCH$_2$-(*R*)Cgl-Aze-Pab-Z;

(2-Me)BnOOCCH$_2$-(*R*)Cgl-Aze-Pab-Z;

ChCH$_2$OOCCH$_2$-(*R*)Cgl-Aze-Pab-Z;

ChOOCCH$_2$-(*R*)Cgl-Aze-Pab-Z;

PhC(Me)$_2$OOCCH$_2$-(*R*)Cgl-Aze-Pab-Z;

(Me)$_2$CHC(Me)$_2$OOCCH$_2$-(*R*)Cgl-Aze-Pab-Z;

BnOOCCH$_2$-(*R*)Cgl-Aze-Pab-COOPh(4-OMe);

ChCH$_2$OOCCH$_2$-(*R*)Cgl-Aze-Pab-COOPh(4-OMe);

(2-Me)BnOOCCH$_2$-(*R*)Cgl-Aze-Pab-COOPh(4-OMe);

EtOOCCH$_2$-(*R*)Cgl-Aze-Pab-COOPh(4-Me);

BnOOCCH$_2$-(*R*)Cgl-Aze-Pab-COOPh(4-Me);

BnOOCCH$_2$-(*R*)Cgl-Aze-Pab-COO-*n*Bu;

*i*PrOOCCH$_2$-(*R*)Cgl-Aze-Pab-COOCH$_2$CH=CH$_2$;

EtOOCCH$_2$-(*R*)Cgl-Aze-Pab-COO-*i*Bu;

BnOOCCH$_2$-(*R*)Cgl-Aze-Pab-COO-*n*Pr;

EtOOCCH$_2$-(*R*)Cgl-Aze-Pab-COOCH$_2$OOCCh;

EtOOCCH$_2$-(*R*)Cgl-Aze-Pab-COOCH2OOCCH$_2$Ch;

EtOOCCH$_2$-(*R*)Cgl-Aze-Pab-COOCH(Me)OOCPh;

EtOOCCH$_2$-(*R*)Cgl-Aze-Pab-COOCH$_2$OOCPh;

BnOOCCH$_2$-(*R*)Cgl-Aze-Pab-COOCH(Me)OAc;

EtOOCCH$_2$-(*R*)Cgl-Aze-Pab-COOCH$_2$OAc;

*t*BuOOCCH$_2$-(*R*)Cgl-Aze-Pab-COOCH$_2$OAc;

MeOOC-C(=CHEt)CH$_2$-OOCCH$_2$-(*R*)Cgl-Aze-Pab-Z;

Men-OOCCH$_2$-(*R*)Cgl-Aze-Pab-COOPh(4-OMe); and

EtOOCCH$_2$-(*R*)Cgl-Aze-Pab-COOCH$_2$CCl$_3$.

32 (currently amended). A formulation~~compound~~ as claimed in Claim 1 wherein the compound of formula I~~which~~ is

EtOOCCH$_2$-(*R*)Cgl-Aze-Pab-COOCH$_2$CCl$_3$;

BnOOCCH$_2$-(*R*)Cgl-Aze-Pab-COO*n*Bu;

*n*PrOOCCH$_2$-*(R)*Cgl-Aze-Pab-Z*;*

Cyclooctyl-OOCCH$_2$-(*R*)Cgl-Aze-Pab-Z;

EtOOCCH$_2$-(*R*)Cgl-Aze-Pab-COOCH$_2$OOCCh;

MeOOCCH$_2$-(*R*)Cgl-Aze-Pab-OH;

EtOOCCH$_2$-(*R*)Cgl-Aze-Pab-OH;

*n*PrOOCCH$_2$-(*R*)Cgl-Aze-Pab-OH;

*i*PrOOCCH$_2$-(*R*)Cgl-Aze-Pab-OH

BnOOCCH$_2$-(*R*)Cgl-Aze-Pab-OH; and

EtOOCCH$_2$-(*R*)Cgl-Aze-Pab-OAc.

33 (currently amended). A formulation~~compoun of formula I~~, as defined in Claim 1, with the additional proviso that, in the compound of formula I, R^1 does not represent -$A^1C(O)OR^4$.

34 (currently amended). A formulation~~compound of formula I~~, as defined in Claim 1, with the additional proviso that, in the compound of formula I, R^4 and R^5 do not independently represent H.

35 (currently amended). A formulation ~~compound of formula I~~, as defined in Claim 1, with the additional proviso that, in the compound of formula I, R^6 does not represent C_{1-17} alkyl, when R^2 represents $OC(O)R^6$.

36 (currently amended). A formulation~~compound of formula I~~, as defined in Claim 1, wherein, in the compound of formula I, R^1 represents $-A^1C(O)OR^4$.

37 (currently amended). A formulation~~compound of formula 1~~, as defined in Claim 1, wherein, in the compound of formula I, R^4 and R^5 independently represent H.

38 (currently amended). A formulation~~compound of formula I~~, as defined in Claim 1, wherein, in the compound of formula I, R^6 represents C_{1-17} alkyl, when R^2 represents $OC(O)R^6$.

39-46 (cancelled).

47 (currently amended). A method of treatment of a condition where inhibition of thrombin is required which method comprises administration of a therapeutically effective amount of a formulation~~compound of formula I~~ as defined in Claim 1 or claim 52, or a pharmaceutically acceptable salt thereof, to a person suffering from, or susceptible to, such a condition.

48 (original). A method as claimed in Claim 47, wherein the condition is

thrombosis.

49 (original). A method as claimed in claim 47, wherein the condition is hypercoagulability in blood and tissues.

50-51 (cancelled).

52 (new). A formulation as claimed in claim 1, wherein the compound of formula I is $EtOOCCH_2$-(R)Cgl-Aze-Pab-OH.

53 (new). A combination comprising (a) acetylsalicylic acid and (b) a compound of the formula I,

$$[R^1O(O)C\text{-}CH_2\text{-}(R)Cgl\text{-}Aze\text{-}Pab\text{-}R^2]$$

54 (new). A combination comprising (a) acetylsalicyclic acid and (b) the compound $EtOOCCH_2$-(*R*)Cgl-Aze-Pab-OH or a pharmaceutically-acceptable salt thereof.

55 (new). A combination comprising (a) acetylsalicyclic acid and (b) the compound $EtOOCCH_2$-(R)Cgl-Aze-Pab-OH.

56 (new). A combination as claimed in Claim 53 which comprises a kit of parts comprising components (a) and (b).

57 (new). A combination product as claimed in Claim 53, in which components (a) and (b) are suitable for sequential, separate and/or simultaneous use in the treatment of a condition where inhibition of thrombin is required.

58 (new). A combination product as claimed in Claim 57, wherein component (a) is combined with component (b).

59 (new). A method of treatment of a condition where inhibition of thrombin is required, which method comprises administration of an effective amount of a combination as claimed in Claim 53.

60 (new). A method of treatment of a condition where inhibition of thrombin is required, which method comprises administration of an effective amount of a combination as claimed in Claim 54.

61 (new). A method of treatment of a condition where inhibition of thrombin is required, which method comprises administration of an effective amount of a combination as claimed in Claim 55.

62 (new). A method of treatment of a condition where inhibition of thrombin is required, which method comprises administration of a therapeutically effective amount of components (a) and (b) of a combination as claimed in Claim 53 separately,

sequentially or simultaneously.

63 (new). A method of treatment of thrombosis or of hypercoagulability in blood and tissues, which comprises administration of an effective amount of a combination as claimed in Claim 53.

64 (new). A method of treatment of thrombosis or of hypercoagulability in blood and tissues, which comprises administration of an effective amount of a combination as claimed in Claim 54.

65 (new). A method of treatment of thrombosis or of hypercoagulability in blood and tissues, which comprises administration of an effective amount of a combination as claimed in Claim 55.